Thrombophilic Risk Factors in Epileptic Children Treated with Valproic Acid

Pediatric Neurology

Volumn 40, Issue 2, 2009, Pages 102-106

  Ünal, Özlem ^a   Deda, Gülhis ^a   Teber, Serap ^a   Ertem, Mehmet ^a   Akar, Nejat ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; PROTEIN C; PROTEIN S; VALPROIC ACID;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; THROMBOPHILIA;

ADOLESCENT; ANTICONVULSANTS; ANTITHROMBIN III; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; INFANT; LIPOPROTEIN(A); MALE; PROTEIN C; PROTEIN S; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA; VALPROIC ACID;

EID: 58149158179     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.10.005     Document Type: Article

References (27)

1. Buck M.L. Valproic acid in the treatment of pediatric seizures. Pediatric pharmacotherapy: a monthly review for health care professionals 3 3 (1997). http://www.healthsystem.virginia.edu/internet/pediatrics/pharma-news/home.cfm Available at:
2. Gidal B., Spencer N., Maly M., et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 44 (1994) 1418-1422
3. Kreuz W., Linde R., Funk M., et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 33 (1992) 178-184
4. Tetzlaff J.E. Intraoperative defect in haemostasis in a child receiving valproic acid. Can J Anaesth 38 (1991) 222-224
5. Zeller J.A., Schlesinger S., Runge U., and Kessler C. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 40 (1999) 186-189
6. Banerjea M.C., Diener W., Kutschke G., Schneble H.J., Korinthenberg R., and Sutor A.H. Pro- and anticoagulatory factors under sodium valproate-therapy in children. Neuropediatrics 33 (2002) 215-220
7. Apeland T., Mansoor M.A., Strandjord R.E., and Kristensen O. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand 101 (2000) 217-223
8. Aynaci F.M., Orhan F., Örem A., Yildirmiş S., and Gedik Y. Effect of antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J Child Neurol 16 (2001) 367-369
9. Boulos P., Kouroukis C., and Blake G. Superior sagittal sinus thrombosis occurring at high altitude associated with protein C deficiency. Acta Haematol 102 (1999) 104-106
10. Gruppo R., Degrauw A., Fogelson H., Glauser T., Balasa V., and Gartside P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr 137 (2000) 714-718
11. Heckmann J.G., Tomandl B., Erbguth F., Neidhardt B., Zingsem H., and Neundörfer B. Cerebral vein thrombosis and prothrombin gene (G20210A) mutation. Clin Neurol Neurosurg 103 (2001) 191-193
12. Lam C.W., Lau C.H., Williams J.C., Chan Y.W., and Wong L.J. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 156 (1997) 562-564
13. Schwaninger M., Ringleb P., Winter R., et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 40 (1999) 345-350
14. Verrotti A., Pascarella R., Trotta D., Giuva T., Morgese G., and Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 41 (2000) 253-257
15. Akar N., Akar E., Deda G., Sipahi T., and Orsal A. Factor V 1691 G-A, prothrombin 20210 G-A, and methyleneetraydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct. J Child Neurol 14 (1999) 749-751
16. Altuntas N., Soylu K., Suskan E., and Akar N. Homocysteine levels in Turkish children. Turk J Haematol 21 (2004) 79-82
17. Ugras M., and Yaki{dotless}nci{dotless} C. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. Brain Dev 28 (2006) 549-553
18. 12 and folic acid. Brain Dev 25 (2003) 113-115
19. Vilaseca M.A., Monrós E., Artuch R., et al. Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B vitamins, and the 677 C→T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol 4 (2000) 269-277
20. Merouani A., Genest Jr. J., Rozen R., et al. Cerebral vascular complication and hyperhomocysteinemia in a cystinotic uremic child. Pediatr Nephrol 13 (1999) 73-76
21. Verrotti A., Domizio S., Angelozzi B., Sabatino G., Morgese G., and Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Pediatr Child Health 33 (1997) 242-245
22. Verrotti A., Basciani F., Domizio S., Sabatino G., Morgese G., and Chiarelli F. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 19 (1998) 364-367
23. Pita-Calandre E., Rodríguez-López C.M., Cano M.D., and Peña-Bernal M. Serum lipids, lipoproteins and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid or phenytoin. [In Spanish]. Rev Neurol 27 (1998) 785-789
24. Akar N. Site specific mutagenesis: Usage for the mutation detection in thrombosis. Turk J Haematol 15 (1998) 123-124
25. Chattergoon D.S., McGuigan M.A., Koren G., Hwang P., and Ito S. Multiorgan dysfunction and disseminated intravascular coagulation in child receiving lamotrigine and valproic acid. Neurology 49 (1997) 1442-1444
26. Khera K.S. Valproic acid induced placental and teratogenic effects in rats. Teratology 45 (1992) 603-610
27. Ohtani K., Tagawa T., Niki Y., and Okamoto N. Disseminated intravascular coagulation in an epileptic infant under the treatment with sodium valproate. No To Hattatsu 24 (1992) 293-295